News & Trends - Biotechnology
Coronavirus vaccine days away from testing, according to Queensland researchers
A University of Queensland team has met a key milestone in their fast-tracked research to develop a vaccine for the coronavirus, COVID-19.
In just three weeks, the team of researchers has created their first vaccine candidate in the laboratory and will move immediately into further development with animal testing before formal pre-clinical testing is initiated.
The proof-of-concept milestone comes after the project’s announcement on 24 January as part of the Coalition for Epidemic Preparedness Innovations (CEPI) rapid response program.
UQ Vice-Chancellor and President Professor Peter Høj AC said the team has shown considerable progress in line with the highly accelerated time frame of the rapid response program, and the long hours in the lab have paid off with this achievement.
“There is still extensive testing to ensure that the vaccine candidate is safe and creates an effective immune response, but the technology and the dedication of these researchers means the first hurdle has been passed,” Professor Høj said.
Register FREE to receive the latest industry news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.
The work in the lab shows the feasibility of using UQ’s ‘molecular clamp’ technology to engineer a vaccine candidate that could be more readily recognised by the immune system, triggering a protective immune response.
Vaccines take many years to develop from concept to licence and use in the community. UQ is aiming for somewhere between 12 and 18 months, which is remarkably quick.
The next stage is to produce this on a larger scale needed for additional testing, to determine its effectiveness against the virus.
Researchers said the early research had gone ‘as expected’ and the material created had the properties which allowed the team to proceed with vaccine development.
The coronavirus has infected more than 77,000 people globally and over 2,300 people have lost their lives.
The group continues to work to a much-accelerated timetable to keep on track for investigational clinical testing after the middle of the year.
UQ is one of only three programs globally, and the only one in Australia, initiated by the Coalition for Epidemic Preparedness Innovations (CEPI), leveraging ‘rapid response’ platforms in response to the novel coronavirus outbreak.
Enhance corporate branding and boost thought
leadership to attract and retain quality employees. How
does your company culture measure up in the industry, according to results from
employee feedback? Get the benchmark analysis by contacting us.
News & Trends - Pharmaceuticals
Heart Week: Uniting patient and cardiologist voices in shaping a new future for patient outcomes
Coinciding with the start of the Heart Week (9 – 12 May), Professor Gemma Figtree, Interventional Cardiologist and Immediate Past […]
MoreNews & Trends - MedTech & Diagnostics
‘It’s a marathon not a sprint’: Industry leaders chart next steps in medtech’s sustainability journey
Ahead of World Environment Day in June, Jane Crowe, Managing Director of Cardinal Health Australia and New Zealand and Pravin […]
MoreNews & Trends - Pharmaceuticals
Vaccination accounts for almost half of mortality decline in infants
Pharma News: Researchers have mapped the impact of vaccines to mark the 50-year anniversary of the Expanded Programme on Immunisation […]
MoreNews & Trends - Pharmaceuticals
AbbVie, Pfizer and Bayer therapies to be considered at upcoming PBAC intracycle meeting
Pharma News: Therapies from AbbVie, Pfizer and Bayer are due to be considered at the Pharmaceutical Benefits Advisory Committee (PBAC) […]
More